Press releases

Oncgnostics GmbH Presents New Clinical Data on GynTect® Precision Diagnostics at EUROGIN 2018

,

Oncgnostics will discuss new clinical data with gynaecological key opinion leaders at EUROGIN 2018 SAN FRANCISCO, CA, USA, November 29, 2018 — Oncgnostics GmbH presents new clinical data on GynTect® […]

Read more
/by

Cervical Cancer Screening: oncgnostics Closes further Investment Round

Das oncgnostics-Teamoncgnostics GmbH

Jena, October 17, 2018 – The Thuringian molecular diagnostics company oncgnostics, which quickly and successfully closed a 750,000 Euros crowd-investing round on Seedmatch early in 2018, now announces the closing […]

Read more
/by

Oncgnostics GmbH retains Biotech Alliances International Inc. to support global partnering and distribution strategy.

Logo Biotech Alliances International

2018-10-02 San Francisco/Jena, Germany: Biotech Alliances International Inc., a Silicon Valley-based healthcare-focused investment bank, announced today that it will serve as the lead investment banker to Oncgnostics globalisation and partnering […]

Read more
/by

Test for Uterine Cancer in Portugal: Biotech Firm oncgnostics Grants Exclusive Licence for Cancer Screening Test

,
Portugal Partnership

Lisbon/Jena, April 16th 2018 – Speculum S.A. is the exclusive licence partner of oncgnostics GmbH for the screening test GynTect® in Portugal. The test is designed to further specify abnormal […]

Read more
/by

Reliable test for cervical cancer triage now available in Slovakia and the Czech Republic: Biotech company oncgnostics concludes an exclusive partnership with the MEDIREX group

,
Medirex team in Bratislava

Jena, January 31th 2018 – oncgnostics GmbH partners with the MEDIREX Group. MEDIREX thus holds the exclusive rights for marketing the test for early and reliable detection of cervical cancer, […]

Read more
/by

GynTect soon available in China: – oncgnostics grants exclusive license for GynTect to the Chinese SINOPHARM subsidiary CJMT – approval for the Chinese market planned

,
Dr. Xia Xiaokai and Dr. Alfred Hansel, chairman of oncgnostics GmbH. In the background: Yang Xiaoming, chairman of CNBG, Wolfgang Tiefensee, Thuringia's Minister for economics, Dr. Michael Brandkamp, chairman of the High-Tech-Gründerfonds sowie Peter Haug, oncgnostics. photo: Christoph Worsch

Jena, April 5th, 2017: The Chinese pharma company Changchun Jienuo Medical Technology (CJMT), a subsidiary of the Chinese state-owned SINOPHARM Group (www.sinopharm.com/en), has purchased an exclusive license from oncgnostics (www.oncgnostics.com) […]

Read more
/by

oncgnostics presents extended version of its cervical cancer diagnostics test GynTect at MEDICA

Jena, November 9th, 2016 – The biotech company oncgnostics (www.oncgnostics.com) will present its new version of the triage test GynTect – a test for the fast and reliable detection of […]

Read more
/by

Early detection of cervical cancer: „GynTect 2.0“- wider range of application by using a greater variety of patient samples

New version of cervical cancer triage test GynTect available

Jena, September 20th, 2016 – GynTect, a molecular diagnostic test developed by the biotech company oncgnostics, allows fast and reliable diagnostics of cervical cancer and the corresponding precancerous stages. The […]

Read more
/by

Oncgnostics GmbH cooperates with SAYRE Therapeutics in India

oncgnostics cooperates with Sayre

Bangalore/Jena, 28.04.2016 – The biotech firm oncgnostics GmbH will start distributing its molecular diagnostic test GynTect for use in cervical cancer diagnostics in an exclusive partnership with Sayre Therapeutics. GynTect […]

Read more
/by

Greiner Bio-One starts international marketing of the cervical cancer triage test GynTect

Jena / Frickenhausen, January 20th, 2016 – With the start of 2016 the distribution of the cervical cancer triage test GynTect® by Greiner Bio-One has started. For this purpose the […]

Read more
/by